ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

LIPO Lipella Pharmaceuticals Inc

0.67
0.0108 (1.64%)
Last Updated: 15:31:06
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,096
Bid Price 0.655
Ask Price 0.67
News -
Day High 0.68

Low
0.6011

52 Week Range

High
2.71

Day Low 0.646
Company Name Stock Ticker Symbol Market Type
Lipella Pharmaceuticals Inc LIPO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0108 1.64% 0.67 15:31:06
Open Price Low Price High Price Close Price Prev Close
0.65 0.646 0.68 0.6592
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
101 5,096 $ 0.657484 $ 3,351 - 0.6011 - 2.71
Last Trade Time Type Quantity Stock Price Currency
15:42:41 17 $ 0.6625 USD

Lipella Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.13M 6.25M - 450k -4.62M -0.74 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Lipella Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LIPO Message Board. Create One! See More Posts on LIPO Message Board See More Message Board Posts

Historical LIPO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.660.680.60110.65250357,0200.011.52%
1 Month0.7550.7850.60110.695260231,161-0.085-11.26%
3 Months0.790.7960.60110.713168927,135-0.12-15.19%
6 Months1.061.300.60110.815778240,036-0.39-36.79%
1 Year2.042.710.60111.96216,193-1.37-67.16%
3 Years7.027.720.60112.51310,411-6.35-90.46%
5 Years7.027.720.60112.51310,411-6.35-90.46%

Lipella Pharmaceuticals Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Your Recent History

Delayed Upgrade Clock